{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:33:10Z","timestamp":1793309590233,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008993","name":"Sveu\u010dili\u0161te u Zagrebu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117761","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:13:27Z","timestamp":1791846807000},"page":"117761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comprehensive analysis of peptide pharmaceutical: Development of three orthogonal chromatographic methods and characterization of bivalirudin degradation products by high-resolution mass spectrometry"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3316-5763","authenticated-orcid":false,"given":"Andreja","family":"Vukoja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Pavi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5332-3624","authenticated-orcid":false,"given":"Sanja","family":"Galovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-1791","authenticated-orcid":false,"given":"Nives","family":"Gali\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117761_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","article-title":"Bivalirudin","volume":"99","author":"Warketin","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jpba.2026.117761_bib2","unstructured":"N. Palepu, R. Motheram, P. Shah, G.. Krishna Ready-to-use Bivalirudin Compositions, U.S. Patent Application No. 12\/856,088. Washington, DC: U.S. Patent and Trademark Office; 2010."},{"key":"10.1016\/j.jpba.2026.117761_bib3","unstructured":"R. Motheram Buffer-based Method for Preparing Bivalirudin Drug Product. U.S. Patent No. 7,985,733. Washington, DC: U.S. Patent and Trademark Office; 2011."},{"key":"10.1016\/j.jpba.2026.117761_bib4","unstructured":"F. Chen, S L. Krill Aqueous Buffer-free Bivalirudin Compositions. U.S. Patent No. 20,150,328,317. Washington, DC: U.S. Patent and Trademark Office; 2015."},{"key":"10.1016\/j.jpba.2026.117761_bib5","unstructured":"G. Krishna, G. Musso Pharmaceutical Formulations of Bivalirudin and Processes of Making the Same. U.S. Patent No. 7,582,727. Washington, DC: U.S. Patent and Trademark Office; 2009."},{"key":"10.1016\/j.jpba.2026.117761_bib6","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.xphs.2017.01.019","article-title":"Storage Stability of Bivalirudin: Hydrophilic Versus Lipophilic Solutions","volume":"106","author":"Zupancic","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117761_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jchromb.2003.12.003","article-title":"Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence detection","volume":"802","author":"Farthing","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2026.117761_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpba.2009.12.002","article-title":"Development and validation of a LC\u2013MS\/MS method for determination of bivalirudin in human plasma: Application to a clinical pharmacokinetic study","volume":"52","author":"Pan","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117761_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpha.2012.10.006","article-title":"Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC\u2013MS\/MS: Method development, validation and application to pharmacokinetics","volume":"3","author":"Li","year":"2013","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117761_bib10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1080\/10826076.2011.631263","article-title":"Quantitative determination of bivalirudin in human plasma by ultra-fast liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study","volume":"35","author":"Li","year":"2012","journal-title":"J. Liq. Chromatogr. R. T."},{"key":"10.1016\/j.jpba.2026.117761_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: Influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.jpba.2026.117761_bib12","unstructured":"ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, Guidance for Industry, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 1 Generic (2021) (Guidance for Industry- Synthetic Peptides (fda.gov))."},{"key":"10.1016\/j.jpba.2026.117761_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1208\/s12248-015-9730-z","article-title":"Liquid Chromatography-High resolution Mass Spectrometry for Peptide Drug Quality Control","volume":"17","author":"Zeng","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2026.117761_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1039\/C9AY01998G","article-title":"A simple, sensitive, high-resolution, customized, reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by design approach","volume":"12","author":"Kumar","year":"2020","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2026.117761_bib15","doi-asserted-by":"crossref","unstructured":"USP Monograph, Bivalirudin, https:\/\/doi.org\/10.31003\/USPNF_M9810_03_01.","DOI":"10.31003\/USPNF_M9810_03_01"},{"key":"10.1016\/j.jpba.2026.117761_bib16","doi-asserted-by":"crossref","unstructured":"USP Monograph, Bivalirudin for Injection, https:\/\/doi.org\/10.31003\/USPNF_M9813_02_01.","DOI":"10.31003\/USPNF_M9813_02_01"},{"key":"10.1016\/j.jpba.2026.117761_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","article-title":"Development of validated stability-indicating assay methods-critical review","volume":"28","author":"Bakshi","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117761_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.addr.2006.10.006","article-title":"The role of degradant profiling in active pharmaceutical ingredients and drug products","volume":"59","author":"Alsante","year":"2007","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.jpba.2026.117761_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs \u2013 A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117761_bib20","first-page":"405","article-title":"A review on stability indicating HPLC method development","volume":"4","author":"Rao","year":"2015","journal-title":"WJPPS"},{"key":"10.1016\/j.jpba.2026.117761_bib21","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.1039\/C4RA03637A","article-title":"Validated HPLC-DAD method for stability study of sulbutiamine HCl","volume":"4","author":"Abdelwahab","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2026.117761_bib22","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1039\/C4RA11758A","article-title":"Stability indicating RP-HPLC method for the determination of flubendazole in pharmaceutical dosage forms","volume":"5","author":"Abdelwahab","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2026.117761_bib23","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/jssc.202101034","article-title":"Synthetic pharmaceutical peptides characterization by chromatography principles and method development","volume":"45","author":"Sharma","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2026.117761_bib24","unstructured":"International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, Step 5, 1998. Photostability testing of new active substances and medicinal products Q1B."},{"key":"10.1016\/j.jpba.2026.117761_bib25","unstructured":"International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, Step 5, 2024. Guideline on validation of analytical procedures Q2 (R2)."},{"key":"10.1016\/j.jpba.2026.117761_bib26","article-title":"Application of analytical quality by design (AQbD) for stability-indicating method development for quantification of nevirapine and its degradation products","volume":"199","author":"Lopes","year":"2024","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2026.117761_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chemolab.2024.105243","article-title":"Recent applications of analytical quality-by-design methodology for chromatographic analysis: A review","volume":"254","author":"Xuan","year":"2024","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"10.1016\/j.jpba.2026.117761_bib28","article-title":"Development and optimization of a LC-MS\/MS compatible method for quantification of losartan, hydrochlorothiazide and their impurities using AQbD approach and measurement uncertainty evaluation","volume":"259","author":"Roca","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2026.117761_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trac.2017.10.028","article-title":"Quality by Design' approach for the analysis of impurities in pharmaceutical drug products and drug substances","volume":"101","author":"Dispas","year":"2018","journal-title":"TrAC. Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117761_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpba.2018.07.050","article-title":"Risk-based approach for method development in pharmaceutical quality control context: A critical review","volume":"161","author":"Deidda","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117761_bib31","unstructured":"International Council for harmonization of technical requirements for pharmaceuticals for human use, ICH harmonized guideline, Step 2, 2022. Analytical procedure development Q14."},{"key":"10.1016\/j.jpba.2026.117761_bib32","doi-asserted-by":"crossref","unstructured":"United States Pharmacopoeia, General Chapter <1220>, official as of May 2022, https:\/\/doi.org\/10.31003\/USPNF_M10975_02_01.","DOI":"10.31003\/USPNF_M10975_02_01"},{"key":"10.1016\/j.jpba.2026.117761_bib33","first-page":"42","article-title":"Effect of Water on the Chemical Stability of Amorphous Pharmaceuticals: 2. Deamidation of Peptides and Proteins","volume":"107","author":"Dehart","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117761_bib34","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.xphs.2022.02.002","article-title":"A Mass Spectrometric Characterization of Light-Induced Modifications in Therapeutic Proteins","volume":"111","author":"Zhang","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117761_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00726-009-0440-7","article-title":"Profiling of residue-level photo-oxidative damage in peptides","volume":"39","author":"Grosvenor","year":"2010","journal-title":"Amino Acids"},{"key":"10.1016\/j.jpba.2026.117761_bib36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1011-1344(01)00208-1","article-title":"Photo-oxidation of proteins and its role in cataractogenesis","volume":"63","author":"Davies","year":"2001","journal-title":"J. Photochem. Photobiol. B"},{"key":"10.1016\/j.jpba.2026.117761_bib37","doi-asserted-by":"crossref","first-page":"10835","DOI":"10.1021\/acs.joc.8b01545","article-title":"Photosensitized cross-linking of tryptophan and tyrosine derivatives by rose bengal in aqueous solutions","volume":"83","author":"Ludvikova","year":"2018","journal-title":"J. Org. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526004292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:26:46Z","timestamp":1793309206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526004292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":37,"alternative-id":["S0731708526004292"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117761","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of peptide pharmaceutical: Development of three orthogonal chromatographic methods and characterization of bivalirudin degradation products by high-resolution mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117761"}}